SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder – Medical Marijuana Program Connection
The cannabis oil will be used as a part of the Company‘s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) —…
Read more SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder – Medical Marijuana Program Connection